Lenvima and Nephrotic syndrome - a phase IV clinical study of FDA data

Summary:

Nephrotic syndrome is reported as a side effect among people who take Lenvima (lenvatinib mesylate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Keytruda, and have Thyroid cancer.

The phase IV clinical study analyzes which people have Nephrotic syndrome when taking Lenvima. It is created by eHealthMe based on reports of 21,107 people who have side effects when taking Lenvima from the FDA, and is updated regularly.

What is Lenvima?

Lenvima has active ingredients of lenvatinib mesylate. eHealthMe is studying from 21,113 Lenvima users. Check the latest studies of Lenvima.

What is Nephrotic syndrome?

Nephrotic syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema) is found to be associated with 624 drugs and 1,072 conditions by eHealthMe. Check the latest studies of Nephrotic syndrome.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

21,107 people reported to have side effects when taking Lenvima.
Among them, 93 people (0.44%) have Nephrotic syndrome.

Among these 93 people:

How long have people been on Lenvima when they have Nephrotic syndrome? *

What is the gender of people who have Nephrotic syndrome when taking Lenvima? *

female: 51.11 %
male: 48.89 %

What is the age of people who have Nephrotic syndrome when taking Lenvima? *

What are other drugs people take besides Lenvima? *

Keytruda: 22 people, 23.66%
Amlodipine: 13 people, 13.98%
Furosemide: 4 people, 4.30%
Levothyroxine Sodium: 4 people, 4.30%
Dayvigo: 3 people, 3.23%
Trazodone Hydrochloride: 3 people, 3.23%
Febuxostat: 3 people, 3.23%
Famotidine: 3 people, 3.23%
Nifedipine: 3 people, 3.23%
Calcium Lactate: 3 people, 3.23%

What are other side effects people have besides Nephrotic syndrome? *

High Blood Pressure: 23 people, 24.73%
Thrombocytopenia (decrease of platelets in blood): 11 people, 11.83%
Oedema Peripheral (superficial swelling): 8 people, 8.60%
Malaise (a feeling of general discomfort or uneasiness): 7 people, 7.53%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 7 people, 7.53%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 6 people, 6.45%
Hypokalemia (low potassium): 5 people, 5.38%
Generalised Oedema (swelling all over the body): 4 people, 4.30%
Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 4.30%
Cardiac Failure: 4 people, 4.30%

What are the existing conditions these people have? *

Thyroid Cancer: 31 people, 33.33%
Hepatocellular Carcinoma (liver cancer): 21 people, 22.58%
High Blood Pressure: 17 people, 18.28%
Endometrial Cancer: 12 people, 12.90%
Renal Cell Carcinoma (a kidney cancer): 6 people, 6.45%
Endometrial Cancer Recurrent: 5 people, 5.38%
Papillary Thyroid Cancer: 4 people, 4.30%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 4.30%
Oedema Peripheral (superficial swelling): 2 people, 2.15%
Neoplasm Malignant (cancer tumour): 2 people, 2.15%

* Approximation only. Some reports may have incomplete information.

Do you take Lenvima and have Nephrotic syndrome?

- Check whether Nephrotic syndrome is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lenvima:

Lenvima (21,113 reports)

Browse all side effects of Lenvima:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephrotic syndrome:

Nephrotic syndrome (624 drugs)

Browse all the conditions that are associated with Nephrotic syndrome:

Nephrotic syndrome (1,072 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lenvatinib mesylate (the active ingredients of Lenvima) and Lenvima (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.